ClinicalTrials.gg
RecruitingNCT00686946NRAMPUpdated Nov 28, 2023

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)

An observational study in Pregnancy and Mental Disorders, sponsored by The Alfred. Recruiting at 1 site in Australia. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by The Alfred · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2005; still recruiting 21 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)is an observational, nationwide study involving women of child-bearing age who take antipsychotic medication during pregnancy. It follows the pathway of mother and baby during pregnancy and for the first 12 months of the baby's life, in order to develop evidence-based guidelines for the best use and effect of antipsychotic medication during pregnancy, thereby informing clinical treating teams with regard to the management of their patients in this vulnerable population group.

The investigators hypothesize that the provision of such evidence-based guidelines will improve the management and outcomes for mother and baby during pregnancy, birth and the postnatal phase, providing a positive impact on maternal and child health and wellbeing for present and future generations.

Read the detailed description

The desire to reproduce is both a powerful urge and a basic human right for women regardless of mental health status. Deinstitutionalised treatment for mental illness, better pharmacotherapies, and generally higher expectations for a normal quality of life have the potential to raise the incidence of pregnancy in women with psychosis (Miller, Bloom \& Resnick, 1992). The right of women with mental illness to become parents places responsibility upon health care professionals to ensure sound antenatal and ongoing care is available.

Ethical duty of care aside, good antenatal treatment appears prudent given the greater risk of obstetric complications in women with schizophrenia (Sacker et al, 1996). In a meta analysis of studies examining outcomes for pregnant women with and without schizophrenia, evidence exists of a small but statistically significant increase in the risk of low birth weight and inferior neonatal condition in infants of the schizophrenia cohort (Sacker et al, 1996). A recent meta analysis (Webb, et al, 2005) summarized that exposure to maternal psychotic illness is associated with a "higher than expected" risk of perinatal and infant mortality, including an almost twofold chance of fetal death or stillbirth (p.1052). Jablensky and colleagues (2005) further discovered that women whose psychiatric illness commenced before the birth of their child were significantly more likely to experience obstetric complications than women whose first admission for mental illness was after the delivery. Moreover, the offspring of women with schizophrenia carry with them an increased risk for developing psychosis (Mednick, Parnas \& Schulsinger, 1987). This observation has driven the neurodevelopmental hypothesis about the aetiology of schizophrenia, which posits that alterations to early fetal brain development in utero might lead to a predisposition to the formation of schizophrenia later in life (Lewis \& Murray, 1987). Such perinatal contributions to adult mental health outcomes points to the necessity to provide pregnant women who have psychosis, with proper and specialized treatment.

Despite these clear arguments for a thorough understanding of the needs of pregnant women with schizophrenia, current research is limited. In particular, there is currently very little evidence regarding the use of antipsychotic medication in pregnancy upon fetal development and maternal health. Over the last four decades, intermittent studies have sought to investigate the teratogenicity of the older or typical antipsychotics upon fetal development. Earlier reports were generated from pregnancy outcomes of women treated with these medications for hyperemesis gravidarum, not from women with schizophrenia (Kerns, 1989); as such, it is difficult to extrapolate initial findings across these two cohorts with confidence. Limb defects in children born to women who were given large doses of haloperidol in early pregnancy are outlined in case reports (Goldberg \& Nissam, 1994). Patton and colleagues (2002) also reviewed three other larger studies and concluded that a significant increased chance exists for babies exposed to phenothiazines to develop congenital malformations, compared with the incidence within the general population.

The newer or second generation antipsychotics (SGAs) have not been studied in any great detail; to date, to our knowledge, there have been no blinded or randomized studies examining birth outcomes in women taking SGAs, and these are unlikely given ethical considerations. Prescribing guidelines laid out in MIMS (2003) for all current SGAs include pregnancy as a "special precaution" and despite the gravity of associated risks of teratogenesis, there are few publications examining atypical antipsychotic medication use in pregnant women. In their review, Patton and colleagues (2002) cite four studies on the outcome of clozapine use, noting that for a total five cases no congenital abnormalities were reported, although one infant experienced low grade fever and seizure, with gastroesophageal reflux. Grigoriadis and Seeman (2002) suggest that the increased risk of agranulocytosis and seizures in babies, coupled with the identification of both pregnancy and clozapine as potentially increasing the likelihood of thromboembolisms, render this a medication to be avoided during pregnancy. Twenty-three Olanzapine-exposed pregnancies were observed by Goldstein and colleagues (2000), who found there was no increased risk of spontaneous abortion, stillbirth, prematurity or major malformation. The authors were, however, swift to assert that studies of greater sample sizes and over a protracted time period are necessary before olanzapine can be declared "safe" with confidence.

Thus, clinicians remain in a conundrum; although in general today's antipsychotic drugs produce fewer side effects, are better tolerated by the patient, and more effectively target the symptoms of psychosis, little evidence has been presented to reassure prescribers that their impact upon fetal development is minimal. A proven, evidence based method for achieving a balance between maternal mental health with minimal risk to the fetus must be researched and evidenced. Therefore, we have established The National Register of Antipsychotic Medication in Pregnancy (NRAMP) as a non-interventional means of providing information about pregnancies and outcomes for women with psychosis, and their babies. Not only is NRAMP seeking to record large scale obstetric information in a prospective fashion, including pharmacotherapy during pregnancy and beyond, it is also capitalizing on the opportunity to track alterations to mental health symptoms of women during pregnancy and in the post partum period, and to gather valuable insights into the attitudes of this cohort as they make the transition into parenthood.

The combination of poor psychosocial history, existing involvement with child protection agencies, psychiatric diagnoses and admissions, medications and substance abuse, present many issues affecting outcomes for both mother and child during the perinatal period. Our study involves extensive collaboration between many different clinical groups, and will culminate in an important best-practice resource to improve the quality of life for both present and future generations. The identification of a history of serious mental illness and a planned management strategy are therefore essential if we are to improve outcomes for mother and baby.

This then, is the driving force behind the establishment of The National Register of Antipsychotic Medication in Pregnancy (NRAMP), and is a much-needed strategy to improve the management of serious mental illness for women who become pregnant.

This investigator initiated study has been funded by Janssen-Cilag, AstraZeneca, Hospira, Lilly and the Australian Rotary Health Research Fund. NB: AstraZeneca provided funding up to and including 250 consented participants. The study continues to recruit.

02

Conditions studied

  • Pregnancy
  • Mental Disorders

Browse trials for

Keywords

  • Severe mental illness
  • Antipsychotic medications
  • Pregnancy
  • Evidence-based guidelines
  • Maternal and infant health and wellbeing
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 500 is above the median of 220 across 391 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

The Alfred is the lead sponsor of 47 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women from across Australia who are taking, or have taken, antipsychotic medication during pregnancy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who take antipsychotic medication during pregnancy
  • Women who are pregnant or have had a baby in the last 12 months
  • Women who are living in Australia
  • Women who are able to provide

Exclusion criteria

Exclusion Criteria:

  • Women who do not take antipsychotic medication during pregnancy
  • Women who are not pregnant, or have not had a baby in the last 12 months
  • Women who are unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • NRAMP

    Participants take their antipsychotic medication as prescribed by their clinical treating teams.

06

What researchers measure

Primary outcomes

  1. Participant interviews

    Interviews to gather demographic, social, medical, psychiatric, medication and obstetric history

    Time frame: Antenatal - once per trimester; Postnatal - quarterly for 12 months

Secondary outcomes

  1. Psychopathology measures for the mother

    PANSS (Positive and Negative Syndrome Scale) Questionnaire EPDS (Edinburgh Postnatal Depression Scale)Questionnaire

    Time frame: Antenatal and up to 12 months postnatally

  2. Developmental Milestone measures for the baby

    ASQ-3 (Ages and Stages Questionnaire, Third Edition)

    Time frame: Birth to 12 months of age

07

Study locations

1 of 1 sites recruiting
  • Monash Alfred Pyschiatry Research Centre, Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be shared, for example, in Case Studies, where personal identification is not compromised, which also allows for an aggregate view of data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2005 (actual). Primary completion is estimated for Dec 2025, 251 months after the start.

Of 150 non-industry observational studies under Mental Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 77. This study's planned 251 months is above that.

Counting every sponsor, half of 157 studies reached it within 37 months; a quarter within 13 and three quarters within 77.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2008
First posted
May 30, 2008
StartActual
Jan 2005
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00686946
Lead sponsor
The Alfred
Responsible party
Jayashri Kulkarni, Professor (Chief Investigator, The Alfred) — Principal investigator
First posted
May 30, 2008
Start date
Jan 2005
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 28, 2023

Study contacts

Prof Jayashri Kulkarni, MBBS,FRANZCP
Contact
jayashri.kulkarni@med.monash.edu.au
61-3-9076-6564
Ms Alisa Turbic, BSc
Contact
maprc-nramp@monash.edu
61-3-9076-6591
Prof Jayashri Kulkarni, MBBS,FRANZCP
principal investigator · Monash Alfred Psychiatry Research Centre (MAPrc)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion